Therapy of polymyositis and dermatomyositis

Marie, I.

doi:10.1016/j.lpm.2010.12.012

Cited by 25 publications

(10 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding of the prior steps is essential as how to approach your next patient with muscle weakness and helps you identify a pattern of the disease (Srinivasan and Amato, 2003; Weis and Nolte, 2009; Marie, 2011; Selcen, 2011). The differential diagnosis of any systemic myopathy (please also see Table 1) should include the following:…”

Section: Step 2: Clinical Approach To a Patient With Muscle Weaknessmentioning

confidence: 99%

Stepwise Approach to Myopathy in Systemic Disease

Chawla¹

2011

Front. Neur.

View full text Add to dashboard Cite

Muscle diseases can constitute a large variety of both acquired and hereditary disorders. Myopathies in systemic disease results from several different disease processes including endocrine, inflammatory, paraneoplastic, infectious, drug- and toxin-induced, critical illness myopathy, metabolic, and myopathies with other systemic disorders. Patients with systemic myopathies often present acutely or sub acutely. On the other hand, familial myopathies or dystrophies generally present in a chronic fashion with exceptions of metabolic myopathies where symptoms on occasion can be precipitated acutely. Most of the inflammatory myopathies can have a chance association with malignant lesions; the incidence appears to be specifically increased only in patients with dermatomyositis. In dealing with myopathies associated with systemic illnesses, the focus will be on the acquired causes. Management is beyond the scope of this chapter. Prognosis is based upon the underlying cause and, most of the time, carries a good prognosis. In order to approach a patient with suspected myopathy from systemic disease, a stepwise approach is utilized.

show abstract

Section: Step 2: Clinical Approach To a Patient With Muscle Weaknessmentioning

confidence: 99%

Stepwise Approach to Myopathy in Systemic Disease

Chawla¹

2011

Front. Neur.

View full text Add to dashboard Cite

show abstract

“…For the treatment of PM/DM, high-dose corticosteroids have been used to suppress inflammation and underlying autoimmunity [12].…”

mentioning

confidence: 99%

Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis

Yokoyama

Furuta

Ikeda

et al. 2015

Modern Rheumatology

View full text Add to dashboard Cite

show abstract

“…Treatment of connective tissue diseases (CTD) has advanced with the introduction of molecular-targeted therapies, such as biologics and new classes of immunosuppressants 1,2,3,4 . Corticosteroids, still indispensable for the treatment of CTD, as well as most of the new treatments have the potential to increase susceptibility to infection, and risk of infection should be compared across these medications within a single cohort.…”

mentioning

confidence: 99%